New immune cell therapy tested for aggressive brain cancer
NCT ID NCT06482905
Summary
This is an early-stage trial testing a new type of personalized immune cell therapy called TX103 CAR-T in adults with a specific, aggressive brain cancer (grade 4 glioma) that has returned or worsened after standard treatment. The main goal is to find a safe dose and see how well patients tolerate the treatment. Researchers will also look for early signs that the therapy can help control the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.